Table 1.
Baseline characteristics of patients according to TKI response
| All n ═ 320 | PFS < 36 months n ═ 264 (82.5%) (short-term responder) | PFS ≥ 36 months n ═ 56 (17.5%) (long-term responder) | P value | |
|---|---|---|---|---|
| Age median (range) | 60 (20−89) | 60 (20−89) | 58 (31−81) | 0.45 |
| Gender, n (%) male | 238 (74.3) | 198 (75.0) | 40 (71.4) | 0.53 |
| Histology, n (%) clear cell RCC | 265 (82.8) | 214 (81.0) | 51 (91.0) | 0.52 |
| Previous nephrectomy, Yes n (%) | 254 (79.3) | 200 (75.7) | 54 (96.4) | 0.001 |
| ECOG PS, n (%) ≥ 1 | 142 (44.3) | 124 (46.9) | 18 (32.1) | 0.02 |
| Sarcomatoid feature, Yes n (%) | 46 (14.3) | 37 (10.1) | 9 (16.0) | 0.41 |
| IMDC score, n (%) intermediate-poor | 211 (65.9) | 184 (69.6) | 27 (48.2) | 0.002 |
| Metastatic sites, n (%) | ||||
| Lung | 196 (61.2) | 162 (61.3) | 34 (60.7) | 0.92 |
| Liver | 56 (17.5) | 51 (19.3) | 5 (8.9) | 0.06 |
| Nodal | 145 (45.3) | 122 (46.2) | 23 (41.0) | 0.48 |
| Bone | 129 (40.3) | 115 (43.5) | 14 (25.0) | 0.01 |
| Brain | 41 (12.8) | 40 (15.1) | 1 (1.7) | 0.007 |
| First-line therapy, n (%) | ||||
| Sunitinib | 231 (72.1) | 192 (72.7) | 39 (69.6) | 0.64 |
| Pazopanib | 89 (27.8) | 72 (27.2) | 17 (30.3) | |
| Line of therapy after TKI, n (%) > 1 | 176 (55) | 158 (59.8) | 18 (32.1) | < 0 . 0 0 1 |
IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; ECOG PS: Eastern Cooperative Oncology Group performance status scale; PFS: Progression-free survival; RCC: Renal cell carcinoma; TKI: Tyrosine kinase inhibitor.